US FDA Generic Drug Office Director Uhl Announces Retirement
Executive Summary
Uhl, who shepherded OGD into the user fee era, will retire in February.
You may also be interested in...
FDA's Post-Shutdown ANDA Bolus Could Be Massive
More than 300 generic drug applications might be officially filed when the shutdown ends, substantially increasing stress on assessors and other Office of Generic Drugs staff.
US FDA's Patrick Frey Joins List Of Agency Leadership Departures
Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.
Leader Of US FDA's EU Mutual Recognition Effort Departs For Industry
Dara Corrigan will become Fresenius-Kabi’s VP for global affairs and policy.